B type

Miniature Circuit Breaker Market in North America to grow by USD 75.89 million from 2022 to 2027 | The high demand for miniature circuit breaker from industries drives the market - Technavio

Retrieved on: 
Wednesday, August 30, 2023
Ultimate tensile strength, ABB, Semiconductor, Prevalence, VIEW, Electronics, Aluminium, Steel, USD, LS, Schneider Electric, CAPEX, Mitsubishi Electric, B type, Siemens, Rockwell Automation, Copper, R, Commercial, Safety, Geography, Electrical wiring, Typesetting

The high demand for miniature circuit breaker from industries is notably driving market growth.

Key Points: 
  • The high demand for miniature circuit breaker from industries is notably driving market growth.
  • Key sectors like manufacturing and automotive prioritize safety and efficiency, driving the utilization of advanced miniature circuit breakers for effective circuit protection.
  • This prominent demand for miniature circuit breakers from diverse industries in North America is projected to drive market growth during the forecast period.
  • Significant Miniature Circuit Breaker Market Trends in North America - Technical advancements in miniature circuit breakers are an emerging market trend.

Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting

Retrieved on: 
Tuesday, November 2, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, UC San Diego School of Medicine, Itolizumab, Pharmacokinetics, University, Poster, ACR, Proteinuria, Patient, Lupus, SLE, Headache, SC, Albuminuria, TYPE, CD6, American College of Rheumatology, Biomarker, Type, Inflammation, Kidney disease, American College, Nasdaq, B type, ALCAM, CD4, UPCR, Pharmaceutical industry

These early results in patients with SLE treated with itolizumab are quite promising, said Dr. Kalunian.

Key Points: 
  • These early results in patients with SLE treated with itolizumab are quite promising, said Dr. Kalunian.
  • I look forward to additional data from EQUALISE, including observations from the Type B portion of the study in patients with lupus nephritis.
  • The EQUALISE study is a Phase 1b open-label proof-of-concept multiple ascending-dose clinical study of itolizumab in patients with systemic lupus erythematosus and lupus nephritis.
  • The study is evaluating the safety and tolerability of subcutaneous delivery of itolizumab in patients with systemic lupus erythematosus and lupus nephritis.

EarthTronics Expands Energy-Saving Linear LED Line for Commercial Retrofit Applications

Retrieved on: 
Tuesday, August 10, 2021
Technology, Manufacturing, Other Technology, Commercial Building & Real Estate, Construction & Property, Building Systems, Other Manufacturing, UL, Temperature, Efficiency, Light-emitting diode, Maintenance, PLL-05, Restaurant, Linearity, Program, Time, Mercury, B type, LED, Environment, PLL, DLC, Electric light

Available in stock, the new products provide an energy-saving solution for commercial, municipal, school and university building retrofit applications.

Key Points: 
  • Available in stock, the new products provide an energy-saving solution for commercial, municipal, school and university building retrofit applications.
  • EarthTronics full line of Type B direct wire, or ballast by-pass LED tubes are designed to increase efficiency and reduce future system maintenance.
  • In addition, Type B T5 lamps and long PL lamps (PLLs) are available to provide a solution for often-overlooked retrofit applications.
  • EarthTronics offers high-performance EarthBulb LED light bulbs, T8 and T5 linear LEDs, and LED fixtures that are designed for commercial buildings, hotels, restaurants, retail stores and residential homes.